Neoadjuvant Trial of Capecitabine for Axillary Lymph Node Positive Operable Breast Cancer
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This randomized phase II trial compared pathologic response rates (pCR) of early breast
cancer following neoadjuvant fluorouracil-epirubicin-cyclophosphamide(FEC) and
capecitabine-epirubicin-cyclophosphamide (XEC).